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Introduction: Several aspects of ventilator-associated tracheobronchitis (VAT)—including diagnostic criteria, overlap
with ventilator-associated pneumonia (VAP), and appropriate treatment regimens—remain poorly defined. The objectives
of this study were to survey reported practices in the clinical and microbiological diagnosis of VAT and to evaluate
perceptions of the impact of VAT on patient outcomes.
Methods: We developed a questionnaire consisting of (a) characteristics of the respondent, the ICU, and
hospital; (b) current clinical and microbiological diagnostic approach; (c) empirical antibiotic therapy; and (d) the
perception of physicians regarding the clinical impact of VAT and its implications.
Results: A total of 288 ICUs from 16 different countries answered the survey: 147 (51%) from the Latin American
(LA) group and 141 (49%) from Spain, Portugal, and France (SPF group). The majority of respondents (n = 228;
79.2%) reported making the diagnosis of VAT based on clinical and microbiological criteria, and 40 (13.9%) by
clinical criteria alone. Approximately half (50.3%) of the respondents agreed that patients should receive
antibiotics for the treatment of VAT. Out of all respondents, 269 (93.4%) assume that a VAT episode increases
ICU length of stay, and this perception is greater in the LA group (97.3%) than in the SPF group (89.4%, P <0.05).
Half of the physicians considered that VAT increases the risk of mortality, and this perception is again greater in
the LA group (58.5% versus 41.1%, P <0.05).
Conclusions: Given the possible high incidence of VAT and the perception of its importance as a risk factor for
VAP and mortality, a large multicenter international prospective study would be helpful to validate a consensual
definition of VAT, determine its incidence, and delineate its impact on subsequent VAP occurrence.Introduction
Although mechanical ventilation (MV) is potentially life-
saving, it also carries significant risks and complications.
Of these, ventilator-associated pneumonia (VAP) is one of
the most severe, being associated with increased morbidity
and duration of MV in the intensive care unit (ICU) [1,2].
Ventilator-associated tracheobronchitis (VAT) is believed
to be an intermediate stage between colonization of the
lower respiratory tract and VAP. However, more recent
data suggests that VAT may be a separate entity that may* Correspondence: drmartinloeches@gmail.com
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reproduction in any medium, provided the orcontribute to increased length of ICU stay and longer
duration of MV [3].
Both VAP and VAT are clinically characterized by
presence of fever, mucopurulent bronchial secretions,
and leukocytosis. In contrast to VAP, VAT does not in-
volve the pulmonary parenchyma and, as a result, does
not cause radiographic pulmonary infiltrates. Accurate
diagnosis of VAT is challenging, as many conditions
commonly encountered in critically ill patients (such
purulent secretions, pulmonary edema or acute respira-
tory distress syndrome) can mimic its signs and symp-
toms. The current knowledge on VAT, in contrast to
that on VAP, is recent and limited to a substantially
lower number of large clinical studies. Our main objec-
tives were to document reported practices of clinical andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Survey response rate
Country Total of sent surveys, n (%) Responses, n (%)
Spain 350 (33.8) 92 (26.3)
France 210 (20.3) 32 (15.2)
Portugal 50 (4.8) 17 (34.0)
Brazil 182 (17.6) 61 (33.5)
Colombia 60 (5.8) 22 (38.6)
Argentina 50 (4.8) 17 (34.0)
Chile 30 (2.9) 12 (40.0)
Ecuador 20 (1.9) 12 (60.0)
Peru 20 (1.9) 7 (35.0)
Mexico 20 (1.9) 1 (5.0)
Venezuela 10 (0.9) 4 (40.0)
Uruguay 10 (0.9) 4 (40.0)
Bolivia 10 (0.9) 4 (40.0)
Guatemala 8 (0.8) 2 (25.0)
Costa Rica 5 (0.5) 1 (20.0)
USA 1 (0.1) 1 (100)
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tions of the impact of VAT on patient outcomes. This
will serve as a first step of an international prospective




Physicians with a major role in infection control prac-
tices and ICU clinical management were surveyed, and
only one respondent per ICU was allowed. This study
was approved by the ethics committee of Corporació
Sanitaria Parc Taulí, Sabadell, Spain (reference number
2013515). Informed consent was not required as the sur-
vey consisted of a voluntary anonymous response to a
web-based questionnaire, which did not include patient
data. The web-based survey attempted to assess the
responding physicians’ individual perceptions of current
clinical practices.
Questionnaire
We developed a web-based questionnaire with four parts
(Additional file 1): (a) characteristics of the respondent
and the ICU and hospital, (b) practices of clinical and
microbiological diagnosis of VAT, (c) empirical antibiotic
(ATB) therapy used after diagnosis, and (d) the percep-
tion of physicians regarding the clinical impact of VAT
and the need for treatment. To evaluate diagnostic
factors, we questioned investigations performed (for
example, fiber-optic bronchoscopy versus less invasive
techniques), culture (quantitative or semi-quantitative),
and any complementary imaging studies. Regarding ATB
use, we included questions on the nature of empirical
therapy, combination use, timing of treatment com-
mencement, and the use of inhaled ATB therapy for
treatment of VAT. The questionnaire was concise and
consisted strictly of multiple-choice questions in an attempt
to improve the response rate. It was first developed in
Spanish and then translated into English, French, and Por-
tuguese by the Steering Committee members. We trans-
ferred the surveys to a web platform (ClinicalRec)—a
fine-tuned, hosted web and data-mining platform de-
signed specifically to perform and analyze clinical data—
to collect the data.
Dissemination to target group
The questionnaire was available online from 1 January
to 31 March 2013. It was endorsed by SEMICYUC
(Sociedad Española de Medicina Intensiva, Crítica y Uni-
dades Coronaria), FEPIMCTI (Federación Panamericana
e Ibérica de Sociedades de Medicina Crítica y Terapia
Intensiva), and BRICNET (Brazilian Research in Inten-
sive Care NETWORK). The members of the Steering
Committee (local opinion leaders) were responsible forthe distribution of the survey in their countries. The
questionnaire was sent by e-mail to 1,036 physicians:
610 (58.8%) in Spain (n = 350), Portugal (n = 50), and
France (n = 210), which formed the Spain, Portugal, and
France (SPF) group, and 426 in the Latin American (LA)
group. Table 1 shows the number of surveys sent by
country. The survey was not distributed in the US, al-
though one participant ICU which was part of a research
network actively collaborating with different centers in
Spain was included.
Statistical analysis
Descriptive statistics were used to characterize the study
sample. We used chi-square and Mann-Whitney tests to
compare survey characteristics of study participants and to
make comparisons by country and region. Data were proc-
essed by using the Statistical Package of Social Sciences
(SPSS) 13.0.1 standard version (IBM, Chicago, IL, USA).
Response rates and sample characteristics were analyzed
by using descriptive statistics. In descriptive data analysis,
proportions (percentages) were reported. Statistical signifi-
cance was defined as a P value of less than 0.05.
Results
A total of 288 ICUs from 16 different countries replied
to the survey, representing a response rate of 27.8%
(288/1,036). Fifty-one percent (n = 147) were from the
LA group, and 141 (49%) from the SPF group (Figure 1).
The number of individual responses per country is
shown in Table 1. The main characteristics of the re-
spondents and the ICUs were compared and are also
presented in Table 2. In the SPF group as compared with
ICUs (%) 
Figure 1 Percentage of intensive care units (ICUs) that responded to the survey out of a total of 288 responses. Data are presented
according to the country of origin.
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greater numbers of beds, and were more frequently
university-associated. However, the only ICUs with more
than 50 beds were reported in the LA group. There was
no significant statistical difference when comparing the
response of physicians according to the type of ICU
(university versus non-university ICU), nor when com-
paring the number of ICU beds (less or more than 20).
Diagnosis of ventilator-associated tracheobronchitis
Almost all (99.7%) of the respondents considered that
ventilated patients are at risk of developing VAT. One
hundred two respondents (35.5%) considered that VAT
is more frequent in all ICU ventilated patients irrespect-
ive of the type of admission diagnosis. Eighty-nine
(30.9%) respondents considered that patients admitted
because of medical conditions are at higher risk of
VAT, followed by neurological (n = 53; 8.4%) and surgi-
cal (n = 20; 7.0%) patients.
The majority of respondents (n = 228; 79.2%) make the
diagnosis of VAT on the basis of both clinical and
microbiological criteria. Forty (13.9%) reported using
clinical criteria alone, and 19 (6.6%) consider it as a diag-
nosis of exclusion. Endotracheal aspirates were reported
to be the most frequently used technique for the diagno-
sis of VAT (59.4%), followed by bronchoalveolar lavage
(BAL) (13.9%) and multiple sampling techniques (12.2%).
BAL and mini-BAL techniques were more frequently
employed by the LA group, whereas multiple sample tech-
niques were more commonly used by the SPF group(Table 3), and 47.6% (n = 137) used any bronchoscopic
technique for diagnosis of VAT (Table 4). Whereas the
use of bronchoscopic techniques is part of routine prac-
tice in only 3.1% of respondents, it is used in 35.8% when
the chest x-ray (CXR) is not conclusive and in 8.7% when
ATB treatment is started. Similarly, more than 50% of
physicians requested a computed tomography (CT) scan
to confirm or exclude the diagnosis of VAT, 2.4% as rou-
tine practice, and 48.3% when CXR is inconclusive
(Table 4).
Although the majority of respondents (n = 276; 95.8%)
use microbiological findings to guide ATB treatment,
more than half (n = 170; 59.0%) do not perform a Gram
stain on the respiratory sample. Sixty-six (22.9%) re-
ported that they do not request quantitative cultures of
respiratory secretions as routine practice, and this
occurred more frequently in the SPF group (Table 4).
Treatment of ventilator-associated tracheobronchitis
Approximately half (50.3%) of the respondents agreed
that patients diagnosed with VAT should receive ATBs.
Only 24.3% (n = 70) routinely prescribed ATBs, whereas
42.0% (n = 121) only prescribed ATBs in the presence of
hemodynamic instability. Conversely, 26% (n = 75) of
physicians considered that VAT should not be treated
with ATB, and 7.6% (n = 22) answered that they do not
have a clear opinion on the most appropriate treatment.
A total of 90.3% (n = 260) of the responders indicated
that the duration of MV helped in the decision of ATB
treatment; however, only 50% of them indicated this
Table 3 Techniques used for the diagnosis of ventilator-assoc
Technique Global SPF group
n = 288 n = 141
n (%) n (%)
Endotracheal aspirate (ETA) 171 (59.4) 87 (61.7)
Bronchoalveolar lavage (BAL) 40 (13.9) 12 (8.5)
ETA plus other techniques 35 (12.2) 27 (19.1)
Mini-BAL 21 (7.3) 4 (2.8)a
Protected specimen brush 4 (1.4) 3 (2.1)
No response 17 (5.9) 8 (5.7)
aAll comparisons were made between Spain, Portugal, and France (SPF) and Latin A







n = 288 n = 141 n = 147
n (%) n (%) n (%)
Number of beds
in ICU
>50 beds 11 (3.8) - 11 (7.5) 0.003
21-50 beds 79 (27.4) 40 (28.4) 39 (26.5) 0.82
10-20 beds 140 (48.6) 80 (56.7) 60 (40.8) 0.01
<10 beds 58 (20.1) 21 (14.9) 37 (25.2) 0.04
ICU type
General 278 (96.5) 137 (97.2) 141 (95.9) 0.79
Cardiac surgery 3 (1.0) - 3 (2.0) 0.26
Neurotrauma 2 (0.7) - 2 (1.4) 0.49
Surgical 2 (0.7) 2 (1.4) - 0.46
Respiratory 2 (0.7) 1 (0.7) 1 (0.7) 1.00
Trauma 1 (0.3) 1 (0.7) - 0.98
Number of beds
in hospital
>500 beds 103 (35.8) 79 (56.0) 24 (16.3) <0.001
201-500 beds 107 (37.2) 55 (39.0) 52 (35.4) 0.60
100-200 beds 50 (17.4) 7 (5.0) 43 (29.3) <0.001
<100 beds 28 (9.7) - 28 (19.0) <0.001
Hospital type
Public 188 (65.3) 133 (94.3) 55 (37.4) <0.001
Private 78 (27.1) 5 (3.5) 73 (49.7) <0.001
Mixed 22 (7.6) 3 (2.1) 19 (12.9) 0.002
Academic degree
University 190 (66.0) 104 (73.8) 86 (58.5) 0.009
No university 98 (34.0) 37 (26.2) 61 (41.5) 0.009
aAll comparisons were made between Spain, Portugal, and France (SPF) and
Latin American groups. ICU, intensive care unit.
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option for VAT (Table 5).
Intravenous (IV) monotherapy (62.5%) is the first
choice of ATB treatment for VAT and was more fre-
quently supported by the SPF group, followed by IV
ATB combination (20.8%) and then IV and nebulized
ATB. The use of nebulized ATB is more frequently
reported by the LA group compared with the SPF group
(Table 5).
The majority of respondents (73.3%) started ATB
treatment within 12 hours of VAT diagnosis. Initiation
of treatment after 24 hours of VAT diagnosis was more
commonly reported by the SPF group (12.1%) as com-
pared with the LA group (4.8%). More than half (66.7)
indicated they favored ATB treatment with a duration of
between 7 and 10 days. Half of the respondents pre-
ferred to de-escalate therapy when the results of
microbiology tests are available. Surprisingly, only 24%
indicated a preference for a short course of ATB treat-
ment (<7 days). The empiric antimicrobial regimens
for early- and late-onset VAT are shown in Figures 2
and 3, respectively.
Impact of ventilator-associated tracheobronchitis
Finally, 94.1% (n = 274) of respondents believe that the
development of VAT is associated with longer duration
of MV. Two hundred sixty-nine (93.4%) assume that a
VAT episode is associated with increased ICU length of
stay, and this perception is greater in the LA group
(97.3%) as compared with the SPF group (89.4%, P <0.05).
Half of the physicians considered that VAT increases the
risk of mortality, and this perception is again greater in
the LA group as compared with the SPF group (58.5%
versus 41.1%, P <0.05).
Discussion
This is the first international survey that has aimed to
evaluate perceptions of impact and self-reported prac-
tices in the diagnosis and treatment of VAT. We con-
sider that the present survey is relevant to increase the
current knowledge of VAT. There are several conflictingiated tracheobronchitis





84 (57.1) 0.50 ND
28 (19.0)a 0.01 0.4 (0.2-0.8)
8 (5.4)a 0.001 4.1 (1.7-10.3)
17 (11.6)a 0.009 0.2 (0.07-0.08)
1 (0.7) 0.58 ND
9 (6.1) 1.00 ND
merican groups. CI, confidence interval; ND, not determined; OR, odds ratio.
Table 4 Microbiological techniques and complementary studies used to the diagnosis of ventilator-associated
tracheobronchitis
Questions Global SPF group Latin American group P
value
OR (95% CI)
n = 288 n = 141 n = 147
n (%) n (%) n (%)
Quantitative cultures
Yes 217 (75.3) 97 (68.8)a 120 (81.6) 0.01 0.5 (0.3-0.9)
No 66 (22.9) 42 (29.8)a 24 (16.4) 0.01 2.2 (1.9-3.9)
NR 5 (1.7) 2 (1.4) 3 (2.0) 1.00 ND
Gram stain technique
Yes 116 (40.3) 62 (44.0) 54 (36.7) 0.25 ND
No 170 (59.0) 78 (55.3) 92 (62.6) 0.25 ND
NR 2 (0.7) 1 (0.7) 1 (0.7) 1.00 ND
Bronchoscopy for the diagnosis of VAT
Never 151 (52.4) 73 (51.8) 78 (53.1) 0.92 ND
Only when the chest x-ray is not conclusive 103 (35.8) 50 (35.5) 53 (36.1) 1.00 ND
Only if I decide to start ATBs 25 (8.7) 13 (9.2) 12 (8.2) 0.91 ND
Always 9 (3.1) 5 (3.5) 4 (2.7) 0.95 ND
CT scan for the diagnosis of VAT
Never 142 (49.2) 82 (58.2)a 60 (40.8) 0.005 2.0 (1.2-3.3)
Only when the chest x-ray is not conclusive 139 (48.3) 58 (41.1)a 81 (55.1) 0.02 0.5 (0.3-0.9)
Always 7 (2.4) 1 (0.7) 6 (4.1) 0.14 ND
aAll comparisons were made between Spain, Portugal, and France (SPF) and Latin American groups. ATB, antibiotic; CI, confidence interval; CT, computed
tomography; ND, not determined; NR, no response; OR, odds ratio; VAT, ventilator-associated tracheobronchitis.
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the present survey provides a path toward meaningful
research questions for future clinical studies. The main
conclusions of the present study are that VAT is per-
ceived as a common complication of MV in ICU pa-
tients and is a diagnosis based not only on clinical
criteria but also on non-invasive techniques and micro-
biological confirmation and that half of physicians
surveyed use systemic ATBs to treat VAT as they believe
that VAT is associated with a longer duration of MV and
longer ICU length of stay.
The true incidence of VAT is not currently known.
VAT is recognized by the Centers of Disease Control
and Prevention (CDC)/National Healthcare Safety Net-
work [4] as an individual clinical entity. As the clinical
relevance of VAT seems to be increasing, it is necessary
to further delineate its incidence in a study that applies
a widely accepted definition. A large multicenter inter-
national study is planned in order to answer some of the
questions presented in this survey. The goal of the
present survey was to determine the importance of VAT
and physicians attitudes based on the answers taken
from 288 ICUs in Europe and Latin America.
The majority of respondents (>90%) to the present
survey agreed that patients under MV have a significant
risk of developing VAT, and they perceived that this riskwas even higher in medical patients. This finding is in
opposition to that of the study by Malacarne and col-
leagues [5], who in a prospective epidemiological study
conducted in 71 Italian ICUs with 9,493 consecutive
patients found that surgical patients were more likely to
develop VAT than medical patients (odds ratio (OR) of
1.64). According to the current definition, as recently
published by the CDC, a diagnosis of VAT is made if
there is absence of pneumonia in the x-ray and at least
two of the following findings: (1) fever (>38°C), (2)
cough, (3) new or increased production of sputum, (4)
rhonchi, and (5) wheezing, and at least one of the
following: (a) positive culture obtained by deep tracheal
aspirate or bronchoscopy and (b) positive laboratory test
on respiratory secretions [4].
Similarly, the European Respiratory Society, European
Society of Clinical Microbiology and Infectious Diseases,
and European Society of Intensive Care Medicine task-
force requires a positive culture of respiratory secretions
as a mandatory item in the diagnosis of VAT [6]. In the
present survey, almost 80% of physicians routinely diag-
nosed VAT with the assistance of microbiological studies,
and a minority (13.9%) relied solely on clinical assessment.
As expected, non-invasive techniques were more fre-
quently preferred to obtain samples and achieve microbio-
logical confirmation. Although the use of quantitative
Table 5 Antibiotic treatment of ventilator-associated tracheobronchitis
Questions Global SPF group Latin American group P
valuea
OR (95% CI)a
n = 288 n = 141 n = 147
n (%) n (%) n (%)
All VAT patients should receive ATB treatment?
Yes 121 (42.0) 59 (41.8) 62 (42.2) 1.00 ND
No 75 (26.0) 31 (22.0) 44 (29.9) 0.16 ND
Only in patients with cardiovascular failure 70 (24.3) 41 (29.1) 29 (19.7) 0.08 1.6 (0.9-2.9)
Unknown 22 (7.6) 10 (7.1) 12 (8.2) 0.90
Which is the most appropriate treatment for VAT?
Broad-spectrum IV ATBs 84 (29.2) 37 (26.2) 47 (32.0) 0.34 ND
Narrow-spectrum IV ATBs 20 (6.9) 15 (10.6) 5 (3.4) 0.002 3.3 (1.1-10.9)
Select ATBs according to MV days 145 (50.3) 74 (52.5) 71 (48.3) 0.55 ND
Nebulized ATBs 6 (2.1) 2 (1.4) 4 (2.7) 0.71 ND
Broad-spectrum IV ATBs + nebulized ATBs 7 (2.4) 1 (0.7) 6 (4.1) 0.14 ND
Never 26 (9.0) 12 (8.5) 14 (9.5) 0.92 ND
Which is the most appropriate option for treatment of VAT?
IV ATBs in monotherapy 180 (62.5) 99 (70.2) 81 (55.1) 0.01 1.9 (1.1-3.2)
IV ATBs in combination 60 (20.8) 20 (20.6) 31 (21.1) 0.16 ND
IV ATBs + nebulized ATBs in monotherapy 27 (9.4) 7 (5.0) 20 (13.6) 0.02 0.3 (0.1-0.8)
IV ATBs + nebulized ATBs in combination 16 (5.6) 2 (1.4) 14 (9.5) 0.006 0.1 (0.02-0.6)
No replyTiming to start ATB treatment? 5 (1.7) 4 (2.8) 1 (0.7) 0.34 ND
<12 hours 211 (73.3) 96 (68.1) 115 (78.2) 0.07 0.5 (0.3-1.0)
13-24 hours 44 (15.3) 23 (16.3) 21 (14.3) 0.75 ND
>24 hours 24 (8.3) 17 (12.1) 7 (4.8) 0.04 2.7 (1.01-7.5)
Never ATB treatment 9 (3.1) 5 (3.5) 4 (2.7) 0.95 ND
ATB duration
7-10 days 25 (8.7) 7 (5.0) 18 (12.2) 0.04 0.3 (0.1-0.9)
7-10 day but de-escalation 167 (58.0) 84 (59.0) 83 (56.5) 0.67 ND
14 days 1 (0.3) 0 1 (0.7) 1.00 ND
Until clinical resolution 22 (7.6) 13 (9.2) 9 (6.1) 0.44 ND
<7 days 71 (24.7) 35 (24.8) 36 (24.5) 1.00 ND
No reply 2 (0.7) 2 (1.4) 0 0.90 ND
aAll comparisons were made between Spain, Portugal, and France (SPF) and Latin American groups. ATB, antibiotic; CI, confidence interval; IV, intravenous; MV,
mechanical ventilation; ND, not determined; NR, no response; OR, odds ratio; VAT, ventilator-associated tracheobronchitis.
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ferentiate VAT from colonization, invasive techniques are
not mandatory for VAT diagnosis. It was therefore sur-
prising that invasive techniques are used by almost half of
respondents. This finding is more frequent in the LA
group than the SPF group.
The subjectivity and variability inherent in interpretation
of CXRs in mechanically ventilated patients make chest
imaging ill suited for inclusion in a definition algorithm to
be used for the potential purposes of public reporting,
inter-facility comparisons, and pay-for-reporting and pay-
for-performance programs. Several authors [7,8] have pro-
posed the use of CT lung scans and this recommendationis followed by half of the respondents to the survey. Never-
theless, it is important to consider whether a CT scan for
this purpose is cost-effective and safe for critically ill pa-
tients. Ventilated patients are at high risk for complications
en route, and in addition transport outside the ICU has
been reported to be an independent risk factor for
VAP (OR 2.9, 95% confidence interval 1.4 to 5.7) [8,9].
A recent observational cross-sectional study of adult
patients in the emergency department found that
CXRs demonstrated poor sensitivity and positive pre-
dictive value for detecting pulmonary opacities when
compared with chest CT for routine clinical care












Figure 2 Empiric antibiotic therapy for early ventilator-associated tracheobronchitis. AMC, amoxicillin/clavulanate; AMK, Amikacin; CBP,
carbapenem; CEF3 NPS, third-generation non-Pseudomonal cephalosporins; CEF3 PS, third-generation Pseudomonal cephalosporins; EU, European
Union group; FQ, fluoroquinolones; LA, Latin American group; PTZ, Piperacillin/Tazobactam; Vanco: vancomycin.
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ment of suspected VAT.
The ATB treatment of VAT remains controversial [12].
In the survey, half of the respondents reported that the
duration of MV is an important factor to consider when
deciding on administration of ATBs to patients with
VAT. The use of ATBs in VAT has been evaluated in
two recent randomized controlled trials. Palmer and
colleagues [13] found faster weaning and less use of
systemic ATB when nebulized ATBs were administered.
Nseir and colleagues [14] found a lower mortality rate
and more MV-free days. Although the administration of
aerosolized ATB in patients with uncomplicated VAT is
an attractive approach, it is reported by only the minorityFigure 3 Empiric antibiotic therapy for late ventilator-associated
tracheobronchitis. AMC, amoxicillin/clavulanate; AMK, Amikacin; CBP,
carbapenem; CEF3 NPS, third-generation non-Pseudomonal
cephalosporins; CEF3 PS, third-generation Pseudomonal cephalosporins;
EU, European Union group; FQ, fluoroquinolones; LA, Latin American
group; PTZ, Piperacillin/Tazobactam; Vanco: vancomycin.of the respondents. In our survey, this practice is more
frequent in LA. Well-designed prospective studies are
needed in order to further delineate the best therapeutic
approach for suspected VAT.
We acknowledge limitations to the present survey.
First, the present study may have a bias selection as VAT
may represent an important clinical entity for respon-
dents. Second, although we sought to survey the ICU
physician most involved in the decision-making process
related to ICU infections, it may represent the personal
opinion of the respondents and may not reflect hospital
or country-wide policies. Third, we could not be com-
pletely sure that respondents were not using VAT and
VAP answers in an interchangeable fashion. However,
questions about VAT were formulated with closed an-
swers, and questions related to VAP were made in order
to avoid confusion and misinterpretation between these
two entities. Fourth, we recognize that self-reported
practices in a survey may not reflect actual practice of
the respondents, a limitation inherent in the nature of
all surveys. Finally, this survey comes from only three
European and 13 LA countries and thus cannot repre-
sent the opinions of these entire communities.
Conclusions
VAT is recognized as a frequent complication of MV.
However, subjective components within VAT definition
and diagnosis may impact the reliability and accuracy of
case identification. VAT represents a clinical entity that
is closer to the clinical reality than more strict criteria
usually considered in most clinical published studies.
Given the perceived increasing incidence of VAT and
its importance as a possible risk factor for VAP and
other adverse outcomes, a large multicenter international
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ologic criteria for VAT diagnosis, needs to be performed.
This should aim to validate an accepted definition of VAT,
determine its incidence, and further delineate its impact
on clinically relevant outcomes.
Key messages
 Ventilator-associated tracheobronchitis is perceived
as a frequent complication of mechanical ventilation.
 The diagnosis of ventilator-associated tracheobronchitis
is usually based on a combination of clinical and
microbiological criteria.
 More than half of respondents did not perform a
Gram stain on the respiratory sample and one out of
four did not request a sample for quantitative
culture in the diagnosis of ventilator-associated
tracheobronchitis.
 Half of physicians reported prescribing broad-spectrum
systemic antibiotics for the treatment of
ventilator-associated tracheobronchitis.
 The majority of physicians believed that
ventilator-associated tracheobronchitis is associated
with a longer duration of mechanical ventilation and
longer intensive care unit length of stay.
Additional file
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questionnaire for the ventilator-associated tracheobronchitis (VAT) in the
Intensive Care Unit International Online Survey.
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